Navarrete-Rodríguez EM, Zapata-Tarrés MM, Vizcaíno-Alarcón A, Garduño-Espinosa J, Dorantes-Acosta E, Palomo-Colli MÁ

Language: Spanish
References: 12
Page: 133-137
PDF size: 288.64 Kb.

ABSTRACT

Background. Currently, anthracyclines have been used in ›50% of cancer treatment protocols in children. The clinical usefulness of these agents is limited by the onset of cardiomyopathy whose presence depends on the total dose of drug and usually is irreversible. Echocardiography is used to study detection of anthracycline cardiotoxicity. The aim of this study was to describe the evolution of cardiac function reported by echocardiography for treatment of children with cancer whose medications contain anthracyclines.
Methods. We included pediatric patients diagnosed with osteosarcoma and acute myeloid leukemia treated between January 2006 and May 2011 at the Hospital Infantil de México Federico Gómez. In the clinical files, values were documented for ejection fraction (EF) and fractional shortening (FS) reported before each cycle, using descriptive statistics for reporting results.
Results. The EF experiences virtually no changes until the 6th cycle of treatment to a cumulative dose of 332.5 mg/m²/sc, demonstrating afterwards an accelerated decline. According to the FS, the most significant change occurs after the seventh cycle at a cumulative dose of 450 mg/m²/sc.
Conclusions. Recognizing the damage that occurs during the early stages is a critical step in preventing complications. The challenge is to implement new tools that will allow us to achieve the objective of preventing or diagnosing subclinical disease.

REFERENCES

1. Colombo A, Cipolla C, Beggiato M, Cardinale D. Cardiac toxicity of anticancer agents. Curr Cardiol Rep 2013;15:362-73.

2. Kucharska W, Negrusz-Kawecka M, Gromkowska M. Cardiotoxicity of oncological treatment in children. Adv Clin Exp Med 2012;21:281-288.

3. Allen H, Driscoll D, Shaddy R, Feltes T. Moss and Adams’ Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adults. Philadelphia: Lippincott Williams & Wilkins; 2008.

4. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23:7685-7696.

5. Roca-Alonso L, Pellegrino L, Castellano L, Stebbing J. Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms? Cardiology 2012;122:253-259.

6. Kremer LC, Caron HN. Anthracycline cardiotoxicity in children. N Engl J Med 2004;351:120-121.

7. Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabrò R. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr Drugs 2005;7:67-76.

8. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voûte PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002;13:819-829.

9. Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed 2007;2:567-583.

10. Jones A, Barlow M, Barrett-Lee PJ, Canney P, Gilmour IM, Robb SD, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009;100:684-692.

11. Bovelli D, Plataniotis G, Roila F, ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21(suppl 5):v277-v282.

12. Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011;13:1-10.